In any case, clinical trials for the use of the AA to counteract other neural disorders, such as acute brain injury, amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease, have already been performed [40], and interestingly, S100B is regarded to play a crucial role in pathogenic processes of all previously cited disorders [5]. Here, S100B is linked to early-onset autosomal dominant Alzheimer disease.